Literature DB >> 21505788

The role of risk communication in the care of osteoporosis.

E Michael Lewiecki1.   

Abstract

Risk assessment and communication of risk are essential components in the care of patients with osteoporosis. The risk of fracture in an untreated patient can be estimated with measurement of bone mineral density, consideration of clinical risk factors, and the use of a validated fracture risk assessment algorithm. When fracture risk is high, pharmacologic therapy to reduce the risk of fracture is indicated, provided no contraindications are present. Initiation, compliance, and persistence with therapy may be enhanced when the patient fully understands the risk of fracture if no treatment is given, as well as the expected benefit and potential risks of treatment. Optimal clinical outcomes with treatment may in part depend on the clinician's skill in communicating risk with the patient, understanding the patient's concerns, and reaching a collaborative treatment decision that is medically reasonable and acceptable to the patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505788     DOI: 10.1007/s11914-011-0056-1

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  42 in total

Review 1.  Treating people with information: an analysis and review of approaches to communicating health risk information.

Authors:  A J Rothman; M T Kiviniemi
Journal:  J Natl Cancer Inst Monogr       Date:  1999

2.  A new model of medical decisions: exploring the limits of shared decision making.

Authors:  Simon N Whitney
Journal:  Med Decis Making       Date:  2003 Jul-Aug       Impact factor: 2.583

3.  Informed decision making in outpatient practice: time to get back to basics.

Authors:  C H Braddock; K A Edwards; N M Hasenberg; T L Laidley; W Levinson
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

5.  Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.

Authors:  K Briot; P Ravaud; P Dargent-Molina; M Zylberman; S Liu-Leage; C Roux
Journal:  Osteoporos Int       Date:  2008-07-26       Impact factor: 4.507

6.  Simplified system for absolute fracture risk assessment: clinical validation in Canadian women.

Authors:  William D Leslie; James F Tsang; Lisa M Lix
Journal:  J Bone Miner Res       Date:  2009-02       Impact factor: 6.741

7.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

8.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

9.  Statistical illiteracy undermines informed shared decision making.

Authors:  Wolfgang Gaissmaier; Gerd Gigerenzer
Journal:  Z Evid Fortbild Qual Gesundhwes       Date:  2008

10.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks.

Authors:  N D Nguyen; S A Frost; J R Center; J A Eisman; T V Nguyen
Journal:  Osteoporos Int       Date:  2008-03-07       Impact factor: 4.507

View more
  6 in total

1.  The clinician's guide to prevention and treatment of osteoporosis.

Authors:  M S LeBoff; S L Greenspan; K L Insogna; E M Lewiecki; K G Saag; A J Singer; E S Siris
Journal:  Osteoporos Int       Date:  2022-04-28       Impact factor: 5.071

2.  The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.

Authors:  Michelle Nadler; Shabbir Alibhai; Pamela Catton; Charles Catton; Jennifer Jones
Journal:  Support Care Cancer       Date:  2014-04-03       Impact factor: 3.603

3.  Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drug Healthc Patient Saf       Date:  2011-12-01

4.  Romosozumab, clinical trials, and real-world care of patients with osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Ann Transl Med       Date:  2020-08

Review 5.  Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review.

Authors:  Charlotte Beaudart; Mickael Hiligsmann; Nannan Li; E Michael Lewiecki; Stuart Silverman
Journal:  Osteoporos Int       Date:  2021-09-24       Impact factor: 4.507

Review 6.  Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.

Authors:  Lawrence Drudge-Coates; Tim Van den Wyngaert; Morten Schiødt; H A M van Muilekom; Gaston Demonty; Sven Otto
Journal:  Support Care Cancer       Date:  2020-04-19       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.